A new paradigm for TB drug development is needed—one that focuses on developing not just drugs but entire drug regimens.
The Critical Path to TB Drug Regimens (CPTR) is working to tackle the challenges facing TB drug development. This includes gaining support for a new paradigm of drug development that enables promising combinations of drugs to be tested and developed together to create entirely new multi-drug treatments. This new approach is expected to reduce the time it takes to develop an innovative regimen from decades to years. CPTR is made possible by unprecedented collaboration among pharma companies and strong commitments from public and private partners around the world. More >
Cure All: Christine Lubinkski – Moderator Introduction
CPTR TB Data Standards Public Review: Webinar
Dear CPTR participants and others interested in TB data standards, The Critical Path to TB Drug Regimens (CPTR) Data Standards Workgroup is very pleased to announce that the first consensus TB data standard has been released for public review. Comments are due by May 25, see below for details. To ensure that all
Cure All Event Recap: A briefing on TB drug research
In the lead up to World TB Day, the Critical Path to TB Drug Regimens sponsored Cure All, a briefing on the most promising new TB drug research. Held at the Kaiser Family Foundation, the event featured a panel of senior representatives from a number of US government organizations, as well an announcement of a
These stories link to the WHO's Working Group on New TB Drugs